Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration
نویسندگان
چکیده
منابع مشابه
New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a leading cause of legal blindness in the elderly in the industrialized world and the third major cause of blindness around the globe. Although neovascular AMD is less prevalent than atrophic AMD, it accounts for most cases with severe visual loss from AMD. VEGF seems to be a key contributary factor in the pathophysiology underlying neovascular AMD. Unt...
متن کاملPharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients
PURPOSE To investigate the pharmacogenetic associations between the genetic risk variants of age-related macular degeneration (AMD) and long-term outcome after intravitreal anti-vascular endothelial growth factor (VEGF) treatment in Korean neovascular AMD patients. METHODS This prospective study included 394 treatment-naïve patients (394 eyes) that underwent intravitreal anti-VEGF treatment f...
متن کاملProfile of conbercept in the treatment of neovascular age-related macular degeneration
In developed countries, age-related macular degeneration (AMD) is the leading cause of irreversible blindness in individuals over the age of 65 years. Vascular endothelial growth factor (VEGF) plays a vital role in the formation of neovascular AMD. VEGF regulates angiogenesis, enhances vascular permeability, and drives the formation of choroidal neovascularization. As a result of the introducti...
متن کاملAnti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach
Pegaptanib (Eyetech Pharmaceuticals and Pfizer), which was approved by the FDA at the end of 2004, was the first anti-VEGF therapy for neovascular AMD (3). After approval of bevacizumab (Genentech/ Roche) for cancer therapy and in view of the suspected role of VEGF in wet AMD, systemic intravenous and, later, intravitreal bevacizumab began to be administered off-label to treat neovascular AMD (...
متن کاملVEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
PURPOSE A previously published study demonstrated a pharmacogenetic association between the minor alleles of 2 VEGFR2 single nucleotide polymorphisms (SNPs) and greater improvement in visual acuity (VA) to treatment with ranibizumab, an anti-vascular endothelial growth factor (VEGF) drug, in patients with neovascular age-related macular degeneration (AMD). We evaluated whether this association ...
متن کامل